Prasad V - Search Results

1

US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.

Kim MS, Prasad V. Kim MS, et al. Among authors: prasad v. Cancer. 2020 Oct 1;126(19):4270-4272. doi: 10.1002/cncr.33058. Epub 2020 Jul 9. Cancer. 2020. PMID: 32644193 Free article.

2

Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?

Goldstein DA, Bilal U, Prasad V. Goldstein DA, et al. Among authors: prasad v. Cancer. 2017 Oct 15;123(20):3872-3874. doi: 10.1002/cncr.30868. Epub 2017 Jun 29. Cancer. 2017. PMID: 28662268 Free article. No abstract available.

3

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals.

Lammers A, Wang R, Cetnar J, Prasad V. Lammers A, et al. Among authors: prasad v. Blood Cancer J. 2017 Nov 30;7(12):637. doi: 10.1038/s41408-017-0008-9. Blood Cancer J. 2017. PMID: 29187747 Free PMC article. No abstract available.

4

Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.

Wagner J, Marquart J, Ruby J, Lammers A, Mailankody S, Kaestner V, Prasad V. Wagner J, et al. Among authors: prasad v. BMJ. 2018 Mar 7;360:k668. doi: 10.1136/bmj.k668. BMJ. 2018. PMID: 29514787 Free PMC article.

5

Cancer screening: A modest proposal for prevention.

Kim MS, Nishikawa G, Prasad V. Kim MS, et al. Among authors: prasad v. Cleve Clin J Med. 2019 Mar;86(3):157-160. doi: 10.3949/ccjm.86a.18092. Cleve Clin J Med. 2019. PMID: 30849032 Free article. No abstract available.

6

Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals.

Kim MS, Prasad V. Kim MS, et al. Among authors: prasad v. JAMA Netw Open. 2019 May 3;2(5):e193981. doi: 10.1001/jamanetworkopen.2019.3981. JAMA Netw Open. 2019. PMID: 31099871 Free PMC article.

7

An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.

Chen EY, Raghunathan V, Prasad V. Chen EY, et al. Among authors: prasad v. JAMA Intern Med. 2019 Jul 1;179(7):915-921. doi: 10.1001/jamainternmed.2019.0583. JAMA Intern Med. 2019. PMID: 31135822 Free PMC article. Review.

8

A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda.

Luo J, Nishikawa G, Prasad V. Luo J, et al. Among authors: prasad v. J Cancer Res Clin Oncol. 2019 Sep;145(9):2303-2311. doi: 10.1007/s00432-019-02984-2. Epub 2019 Aug 8. J Cancer Res Clin Oncol. 2019. PMID: 31396700

9

The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.

Kim MS, Prasad V. Kim MS, et al. Among authors: prasad v. JAMA Intern Med. 2020 Feb 1;180(2):315-317. doi: 10.1001/jamainternmed.2019.4694. JAMA Intern Med. 2020. PMID: 31657842 Free PMC article. Review.

10

Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.

Hazim A, Mills G, Prasad V, Haslam A, Chen EY. Hazim A, et al. Among authors: prasad v. J Natl Compr Canc Netw. 2020 Apr;18(4):428-433. doi: 10.6004/jnccn.2019.7375. J Natl Compr Canc Netw. 2020. PMID: 32259790 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,043 results

Search Page

Filters